HCV Platform

HCVAllaChem has been developing novel small molecules with improved pharmacokinetics, efficacy, and safety properties as compared to competitors’ first in class compounds.

Allachem’s drug candidates AV4025 and AVR560 are now in clinical development for HCV. Both molecules possess excellent DMPK/tox properties. AV4205 is currently in pre-clinical studies